Loading...

Anthera Pharmaceuticals

OTCPK:ANTH
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ANTH
OTCPK
$2M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The last earnings update was 375 days ago. More info.


Add to Portfolio Compare Print
  • Anthera Pharmaceuticals has significant price volatility in the past 3 months.
ANTH Share Price and Events
7 Day Returns
-15.7%
OTCPK:ANTH
-0.3%
US Biotechs
-2.1%
US Market
1 Year Returns
-69.6%
OTCPK:ANTH
-5%
US Biotechs
1.3%
US Market
ANTH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Anthera Pharmaceuticals (ANTH) -15.7% -22.2% -26.2% -69.6% -99.7% -99.7%
US Biotechs -0.3% -2.5% -5.2% -5% 4.2% 10.1%
US Market -2.1% -4.2% 0% 1.3% 33.5% 38%
1 Year Return vs Industry and Market
  • ANTH underperformed the Biotechs industry which returned -5% over the past year.
  • ANTH underperformed the Market in United States of America which returned 1.3% over the past year.
Price Volatility
ANTH
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Anthera Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Anthera Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $0.07.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Anthera Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Anthera Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:ANTH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-03-31) in USD $-1.76
OTCPK:ANTH Share Price ** OTCPK (2019-05-24) in USD $0.07
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 17.95x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Anthera Pharmaceuticals.

OTCPK:ANTH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:ANTH Share Price ÷ EPS (both in USD)

= 0.07 ÷ -1.76

-0.04x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anthera Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Anthera Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Anthera Pharmaceuticals's expected growth come at a high price?
Raw Data
OTCPK:ANTH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.04x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.19x
United States of America Market PEG Ratio Median Figure of 2,120 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Anthera Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Anthera Pharmaceuticals's assets?
Raw Data
OTCPK:ANTH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-03-31) in USD $0.21
OTCPK:ANTH Share Price * OTCPK (2019-05-24) in USD $0.07
United States of America Biotechs Industry PB Ratio Median Figure of 418 Publicly-Listed Biotechs Companies 3.19x
United States of America Market PB Ratio Median Figure of 5,207 Publicly-Listed Companies 1.8x
OTCPK:ANTH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:ANTH Share Price ÷ Book Value per Share (both in USD)

= 0.07 ÷ 0.21

0.34x

* Primary Listing of Anthera Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anthera Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Anthera Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Anthera Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Anthera Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Anthera Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.4%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Anthera Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Anthera Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Anthera Pharmaceuticals's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Anthera Pharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:ANTH Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.4%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:ANTH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:ANTH Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
OTCPK:ANTH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-03-31 -32 -25
2017-12-31 -37 -29
2017-09-30 0 -43 -35
2017-06-30 0 -51 -54
2017-03-31 0 -53 -68
2016-12-31 0 -49 -66
2016-09-30 2 -46 -59
2016-06-30 3 -40 -45
2016-03-31 3 -35 -39
2015-12-31 3 -31 -35
2015-09-30 1 -28 -35
2015-06-30 1 -25 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Anthera Pharmaceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if Anthera Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:ANTH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Anthera Pharmaceuticals Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:ANTH Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
OTCPK:ANTH Past Financials Data
Date (Data in USD Millions) EPS *
2018-03-31 -1.76
2017-12-31 -2.86
2017-09-30 -4.19
2017-06-30 -7.84
2017-03-31 -12.21
2016-12-31 -12.87
2016-09-30 -11.56
2016-06-30 -8.94
2016-03-31 -8.11
2015-12-31 -7.91
2015-09-30 -9.01
2015-06-30 -9.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Anthera Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Anthera Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Anthera Pharmaceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Anthera Pharmaceuticals's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Anthera Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Anthera Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Anthera Pharmaceuticals performed over the past 5 years?

  • Anthera Pharmaceuticals's last earnings update was 375 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Anthera Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Anthera Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Anthera Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Anthera Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Anthera Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Anthera Pharmaceuticals Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:ANTH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-03-31 -24.93 8.54
2017-12-31 -29.38 7.94
2017-09-30 0.00 -34.80 10.09
2017-06-30 0.00 -53.77 10.79
2017-03-31 0.00 -68.42 11.74
2016-12-31 0.15 -66.44 11.07
2016-09-30 2.06 -58.68 9.19
2016-06-30 2.80 -44.73 8.78
2016-03-31 3.09 -39.29 7.90
2015-12-31 3.19 -35.22 7.57
2015-09-30 1.27 -35.33 7.47
2015-06-30 0.53 -30.99 6.79
2015-03-31 0.25 -29.35 6.68
2014-12-31 -29.60 6.62
2014-09-30 -31.36 6.50 -9.60
2014-06-30 -30.17 6.55 -5.55
2014-03-31 -31.20 6.65 -0.28
2013-12-31 -30.86 6.56
2013-09-30 -16.51 6.35 21.12
2013-06-30 -22.68 6.47 26.59
2013-03-31 -32.00 6.58 36.19
2012-12-31 -45.33 6.93 24.85
2012-09-30 -79.64 7.50 68.78
2012-06-30 -92.11 7.73 80.80

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Anthera Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Anthera Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Anthera Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Anthera Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Anthera Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Anthera Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Anthera Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Anthera Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Anthera Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Anthera Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Anthera Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Anthera Pharmaceuticals Company Filings, last reported 1 year ago.

OTCPK:ANTH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-03-31 5.46 0.00 8.09
2017-12-31 -5.50 0.00 2.20
2017-09-30 0.34 0.00 6.08
2017-06-30 4.56 0.00 11.15
2017-03-31 2.76 0.00 20.65
2016-12-31 12.85 0.00 20.84
2016-09-30 20.79 0.00 32.57
2016-06-30 20.54 0.00 28.50
2016-03-31 30.82 0.00 37.88
2015-12-31 39.66 0.00 46.95
2015-09-30 45.31 0.00 55.76
2015-06-30 26.92 0.00 35.46
2015-03-31 35.11 0.00 41.65
2014-12-31 -2.26 0.00 2.64
2014-09-30 4.45 7.15 14.56
2014-06-30 10.46 8.39 20.90
2014-03-31 10.83 14.78 23.08
2013-12-31 14.76 17.88 25.95
2013-09-30 22.96 18.57 32.04
2013-06-30 27.60 19.26 38.45
2013-03-31 33.35 18.39 54.39
2012-12-31 -3.53 20.55 24.75
2012-09-30 5.41 22.62 42.46
2012-06-30 -18.55 24.69 22.89
  • Anthera Pharmaceuticals has no debt.
  • Anthera Pharmaceuticals has no debt compared to 5 years ago when it was 55.3%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Anthera Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Anthera Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 14.5% each year.
X
Financial health checks
We assess Anthera Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Anthera Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Anthera Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Anthera Pharmaceuticals dividends.
If you bought $2,000 of Anthera Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Anthera Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Anthera Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:ANTH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:ANTH Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Anthera Pharmaceuticals has not reported any payouts.
  • Unable to verify if Anthera Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Anthera Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Anthera Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Anthera Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Anthera Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Anthera Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Anthera Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Thompson
COMPENSATION $888,377
AGE 51
TENURE AS CEO 2.4 years
CEO Bio

Mr. John Craig Thompson has been Chief Executive Officer & Director since December 06, 2016 and served as the President of Anthera Pharmaceuticals, Inc. since January 7, 2016. Mr. Thompson served as the Chief Operating Officer of Anthera Pharmaceuticals, Inc. since January 7, 2016 until December 2, 2016. He oversees both of Anthera's late stage development programs and commercial preparation efforts. He served as the Chief Operating Officer of Tetraphase Pharmaceuticals, Inc., from February 4, 2014 to December 31, 2015, where he oversaw the development and implementation of the commercial strategy as well as the business development and commercial manufacturing. Prior to Tetraphase Pharmaceuticals, he served as the Chief Commercial Officer of Trius Therapeutics, Inc. since January 10, 2011 until January 2014. He was initially responsible for developing the commercial strategy, positioning and planning for the potential launch of torezolid phosphate, an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections. Mr. Thompson has more than 24 years of pharmaceutical marketing and sales experience. He served as Vice President of Marketing at Pfizer's Specialty Care Business Unit, where he was directly responsible for the U.S. commercial strategy for products with over $1.5 billion in annual U.S. sales including the first generation oxazolidinone Zyvox(R), the anti-infectives Tygacil(R), Vfend(R) and Eraxis(R) as well as Rapammune(R) and Relistor(R). Prior to his 7 years at Pfizer, he served in positions of increasing responsibility during his 12 years at Merck where he most notably worked on the commercial planning and marketing activities for its anti-infectives Primaxin(R), Mefoxin(R) and Cancidas(R) as well as on major cardiovascular brands including Vytorin(R), Zetia(R) and Zocor(R) Mr. Thompson holds a degree in Commerce from McMaster University and an MBA from the University of Notre Dame.

CEO Compensation
  • John's compensation has been consistent with company performance over the past year, both up more than 20%.
  • John's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Anthera Pharmaceuticals management team in years:

2.2
Average Tenure
50.5
Average Age
  • The tenure for the Anthera Pharmaceuticals management team is about average.
Management Team

Paul Truex

TITLE
Executive Chairman
COMPENSATION
$100K
AGE
49

John Thompson

TITLE
CEO & Director
COMPENSATION
$888K
AGE
51
TENURE
2.4 yrs

May Liu

TITLE
Senior VP of Finance & Administration and Principal Accounting Officer
COMPENSATION
$593K
AGE
42
TENURE
5.9 yrs

Paul Adams

TITLE
Senior Vice President of Global Regulatory Affairs and Compliance
AGE
55
TENURE
5.2 yrs

Drew McManigle

TITLE
Chief Liquidating Officer & Director
TENURE
1.3 yrs

Brad Bugdanowitz

TITLE
Secretary

Klara Dickinson-Eason

TITLE
COMPENSATION
$706K
AGE
50
TENURE
1.9 yrs

Chuck Olson

TITLE
COMPENSATION
$799K
AGE
61
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the Anthera Pharmaceuticals board of directors in years:

4.9
Average Tenure
51
Average Age
  • The tenure for the Anthera Pharmaceuticals board of directors is about average.
Board of Directors

Paul Truex

TITLE
Executive Chairman
COMPENSATION
$100K
AGE
49
TENURE
2.4 yrs

John Thompson

TITLE
CEO & Director
COMPENSATION
$888K
AGE
51
TENURE
2.4 yrs

Drew McManigle

TITLE
Chief Liquidating Officer & Director
TENURE
1.3 yrs

Phillip Sager

TITLE
Director
COMPENSATION
$54K
AGE
62
TENURE
4.9 yrs

Brian Mueller

TITLE
Director
COMPENSATION
$55K
AGE
44
TENURE
4.9 yrs

Brent Furse

TITLE
Director
COMPENSATION
$57K
AGE
49
TENURE
3.1 yrs

Chris Henney

TITLE
Director
COMPENSATION
$52K
AGE
77
TENURE
14.1 yrs

Dave Thompson

TITLE
Director
COMPENSATION
$50K
AGE
70
TENURE
13.5 yrs

David Wofsy

TITLE
Member of Scientific Advisory Board
TENURE
11.3 yrs

Kenneth Kalunian

TITLE
Member of Scientific Advisory Board
TENURE
11.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Anthera Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Anthera Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Details
Name: Anthera Pharmaceuticals, Inc.
ANTH
Exchange: OTCPK
Founded: 2004
$1,832,551
26,179,302
Website: http://www.anthera.com
Address: Anthera Pharmaceuticals, Inc.
25801 Industrial Boulevard,
Suite B,
Hayward,
California, 94545,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK ANTH Common Stock Pink Sheets LLC US USD 01. Mar 2010
DB 6TA2 Common Stock Deutsche Boerse AG DE EUR 01. Mar 2010
Number of employees
Current staff
Staff numbers
21
Anthera Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/25 00:21
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2018/03/05
Last earnings filing: 2018/05/15
Last earnings reported: 2018/03/31
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.